The phase III BOLERO‐2 study demonstrated that the combination of everolimus and exemestane significantly prolongs PFS compared to exemestane alone in postmenopausal HR‐positive/HER2‐negative advanced breast cancer patients who have experienced AI treatment failure. This evidence concerns the gene ERBB2 and breast carcinoma.